Cytek Biosciences Past Earnings Performance

Past criteria checks 0/6

Cytek Biosciences's earnings have been declining at an average annual rate of -39.7%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 21.1% per year.

Key information

-39.7%

Earnings growth rate

14.1%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate21.1%
Return on equity-2.6%
Net Margin-5.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Cytek Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:8EQ Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24201-109241
30 Jun 24198-189142
31 Mar 24201-129244
31 Dec 23193-129244
30 Sep 23183-149043
30 Jun 23176-68541
31 Mar 23166-27737
31 Dec 2216426835
30 Sep 22155-16332
30 Jun 22148-35930
31 Mar 22139-25227
31 Dec 2112804624
30 Sep 2112013722
30 Jun 2111023119
31 Mar 219942716
31 Dec 209332414
31 Dec 1958-17179

Quality Earnings: 8EQ is currently unprofitable.

Growing Profit Margin: 8EQ is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8EQ is unprofitable, and losses have increased over the past 5 years at a rate of 39.7% per year.

Accelerating Growth: Unable to compare 8EQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8EQ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).


Return on Equity

High ROE: 8EQ has a negative Return on Equity (-2.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies